SecBot SecBot
8-K ·Filed Mar 5, 2026

CRBU

Caribou Biosciences, Inc.
MIXED
Impact 5/10
Horizonmonths Processed8mo ago SEC0001619856-26-000007
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor upcoming clinical data releases in 2026 for vispa-cel and CB-011, which could be catalysts. Watch for financing activities as the company explores options to fully fund the vispa-cel pivotal trial despite current cash runway into 2H 2027.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.82
T+0 close · Mar 5, 2026 · via day close
Latest settled
+33.52%
T+60 · $2.43
Vs SPY
+20.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $1.82entry
  2. T+1 · 8mo ago +8.24%α +7.40% · $1.97
  3. T+5 · 8mo ago +3.30%α +4.83% · $1.88
  4. T+20 · 8mo ago +7.14%α +9.19% · $1.95
  5. T+60 · 6mo ago +33.52%α +20.74% · $2.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caribou Biosciences reported its 2025 financial results, showing a slight improvement in net loss despite a $21.3M non-cash impairment charge. The company highlighted positive clinical data for its allogeneic CAR-T therapies vispa-cel and CB-011, with longer-term data expected in 2026. Cash reserves decreased to $142.8M but are expected to fund operations into 2H 2027.

Key Financial Metrics

Revenue
$11.2M
+11.7% YoY
Adj. EPS
$-1.36
GAAP: $-1.59

Key Facts

  • Licensing revenue increased to $11.2M in 2025 from $10.0M in 2024
  • R&D expenses decreased to $109.4M in 2025 from $130.2M in 2024
  • GAAP net loss was $148.1M in 2025 vs $149.1M in 2024
  • Non-GAAP net loss improved to $126.8M in 2025 from $149.1M in 2024
  • Cash, cash equivalents, and marketable securities decreased to $142.8M from $249.4M
  • Company expects current cash to fund operations into 2H 2027
  • Presented positive clinical data for vispa-cel and CB-011 at Tandem Meetings
  • Engaging with FDA on pivotal trial design for vispa-cel in 2L LBCL

Financial Impact

Net loss decreased by $1M YoY despite $21.3M impairment charge, with cash burn of $106.6M for the year

revenueepscashFlowdilution

Risk Factors

  • Significant cash burn with $106.6M used in 2025
  • Need for additional funding to fully support pivotal trial for vispa-cel
  • Clinical trial risks and regulatory approval uncertainties
  • Recent insider selling of $47K in the past 30 days

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001619856-26-000007
Document: crbu-20260305.htm0001619856-26-000007
Document: 0001619856-26-000007-index-headers.html0001619856-26-000007
Document: 0001619856-26-000007-index.html0001619856-26-000007
Document: 0001619856-26-000007.txt0001619856-26-000007

Track record

13 reports on CRBU

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
  2. Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
  3. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
  4. Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  5. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  6. Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
  8. Mar 5, 202636w ago 8-K Mixed 5/10 Viewing Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  9. Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  10. Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026